Cytomegalovirus Infections Clinical Trial
Official title:
Phase I/II Study of Human Anti-Cytomegalovirus (CMV) Monoclonal Antibody MSL-109 in Newborns With Symptomatic Congenital CMV Infection Without Central Nervous System Disease
OBJECTIVES: I. Evaluate the safety, tolerance, and potential efficacy of 3 doses of human
anti-cytomegalovirus (CMV) monoclonal antibody SDZ MSL-109 (MOAB MSL-109) in the treatment
of newborns with congenital CMV infection and no central nervous system disease.
II. Determine the relationship between plasma concentrations of MOAB MSL-109 and therapeutic
outcome.
III. Determine whether MOAB MSL-109 influences the antibody response and clearance of virus
from the urine.
PROTOCOL OUTLINE: Patients are treated with human anti-cytomegalovirus monoclonal antibody
MSL-109, administered intravenously every other week for a total of 3 doses.
Groups of 6 patients are treated at each of 3 MSL-109 doses; there is no intrapatient
escalation.
No concurrent therapy with antibiotics for systemic infection, parenteral antifungal agents,
biological response modifiers, or other antiviral agents is allowed.
Patients are followed every 2 weeks for 6 weeks, every 4 weeks for 12 weeks, then annually
for 5 years.
;
Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT03950414 -
A Dose-Escalation Study Evaluating Safety and Tolerability of Viral-Specific T Cells Against CMV in Adult Solid Organ Transplant Recipients
|
Phase 1 | |
| Recruiting |
NCT04690933 -
AntiCMV molécules Monitoring in Real-life in Stem Cell Recipients
|
||
| Withdrawn |
NCT04936971 -
Introduction of mTor Inhibitors and the Activation of the Cytomegalovirus (CMV) -Specific Cellular Immune Response
|
Phase 4 | |
| Recruiting |
NCT02671318 -
Conversion to Sirolimus: Effects in Cytomegalovirus Infection Recurrence
|
Phase 4 | |
| Completed |
NCT01325636 -
Injection of CD4 and CD8 + T Cells Anti-Cytomegalovirus (CMV) or Anti-adenovirus
|
Phase 1/Phase 2 | |
| Recruiting |
NCT00228202 -
Genotyping of Cytomegalovirus From Patients in Israel
|
N/A | |
| Completed |
NCT00031421 -
Neonatal CMV-Ganciclovir Follow-up Study
|
N/A | |
| Completed |
NCT00005496 -
Inflammation, Infection, and Future Cardiovascular Risk
|
N/A | |
| Terminated |
NCT03262194 -
Relevance of Gastric Aspirate in HCMV Detection
|
||
| Completed |
NCT04478474 -
Cytomegalovirus (CMV) Viremia and Disease Occurrence in Pediatric Allogeneic Stem Cell Transplantation Recipients
|
||
| Recruiting |
NCT05370976 -
Efficacy and Safety of Cytotect®CP, Hyperimmune Anti-CMV IVIg as CMV Prophylaxis in Patients Developing Acute Grade II-IV GVHD After Allogeneic Hematopoietic Cell Transplantation.
|
Phase 2 | |
| Active, not recruiting |
NCT02943057 -
Topical 2% Ganciclovir Eye Drop for CMV Anterior Uveitis / Endotheliitis
|
Phase 4 | |
| Completed |
NCT02538172 -
Cell-mediated Immunity for Prevention of CMV Disease
|
N/A | |
| Completed |
NCT02642822 -
The Epidemiologic Study of Human Cytomegalovirus（CMV） in Female Students of Xiamen University
|
N/A | |
| Completed |
NCT02134184 -
The Influence of Chronic CMV Infection on Influenza Vaccine Responses
|
Phase 4 | |
| Completed |
NCT00673868 -
Cytomegalovirus (CMV) Specific Cytotoxic T Lymphocytes (CTL) When Used for Prophylaxis Against CMV in Recipients of Allogeneic, T Cell Depleted Stem Cell Transplants
|
Phase 1 | |
| Active, not recruiting |
NCT05089630 -
A Study of Safety and Immune Response to Different Doses of a Cytomegalovirus Vaccine in Healthy Adults
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06058858 -
Incidence and Risks Factors of CMV Reactivation in Patients Receiving of CAR-T Cells for Acute Leukemia and Lymphoma Relapse, a Cohort Study Analysis
|
||
| Active, not recruiting |
NCT04904614 -
Letermovir Use in Heart Transplant Recipients
|
Phase 4 | |
| Completed |
NCT01986010 -
Safety, Tolerability, and Immunogenicity of the Human Cytomegalovirus Vaccine (V160) in Healthy Adults (V160-001)
|
Phase 1 |